1. Low expression of Talin1 is associated with advanced pathological features in colorectal cancer patients
- Author
-
Elmira Gheytanchi, Marzieh Ebrahimi, Zahra Madjd, Mahdi Alemrajabi, Somayeh Vafaei, Zohreh Habibi Shams, Marzieh Naseri, Fahimeh Fattahi, and Leili Saeednejad Zanjani
- Subjects
Oncology ,Adult ,Male ,Talin ,medicine.medical_specialty ,Colorectal cancer ,Carcinogenesis ,lcsh:Medicine ,Article ,Metastasis ,Young Adult ,Predictive Value of Tests ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Stage (cooking) ,lcsh:Science ,Pathological ,Gene ,Aged ,Neoplasm Staging ,Cancer ,Aged, 80 and over ,Univariate analysis ,Multidisciplinary ,Tissue microarray ,business.industry ,lcsh:R ,Middle Aged ,medicine.disease ,Prognosis ,Survival Analysis ,digestive system diseases ,Gene Expression Regulation, Neoplastic ,Colonic Neoplasms ,Immunohistochemistry ,lcsh:Q ,Female ,business ,Colorectal Neoplasms ,Biomarkers - Abstract
To explore the proper prognostic markers for the likelihood of metastasis in CRC patients. Seventy-seven fresh CRC samples were collected to evaluate the mRNA level of the selected marker using Real-time PCR. Moreover, 648 formalin-fixed paraffin-embedded CRC tissues were gathered to evaluate protein expression by immunohistochemistry (IHC) on tissue microarrays. The results of Real-Time PCR showed that low expression of Talin1 was significantly associated with advanced TNM stage (p = 0.034) as well as gender (p = 0.029) in mRNA levels. Similarly, IHC results indicated that a low level of cytoplasmic expression of Talin1 was significantly associated with advanced TNM stage (p = 0.028) as well as gender (p = 0.009) in CRC patients. Moreover, decreased expression of cytoplasmic Talin1 protein was found to be a significant predictor of worse disease-specific survival (DSS) (p = 0.011) in the univariate analysis. In addition, a significant difference was achieved (p = 0.039) in 5-year survival rates of DSS: 65% for low, 72% for moderate, and 88% for high Talin1 protein expression. Observations showed that lower expression of Talin1 at both the gene and protein level may drive the disparity of CRC patients’ outcomes via worse DSS and provide new insights into the development of progression indicators because of its correlation with increased tumor aggressiveness.
- Published
- 2020